Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17789739 | 1.00 | KMT2A (0.32) | KMT2AMAPTROCK2PDE4BIGF1R | |
| SCHEMBL16377788 | 0.95 | MAPT (0.32) | MAPTIGF1R | |
| SCHEMBL17789738 | 0.90 | KMT2A (0.31) | KMT2AMAPTTRPV1TTK | |
| SCHEMBL22626622 | 0.90 | KMT2A (0.31) | KMT2AMAPTTRPV1TTK | |
| SCHEMBL17789695 | 0.90 | KMT2A (0.31) | KMT2AMAPTTRPV1TTK | |
| SCHEMBL16377840 | 0.90 | HPGDS (0.33) | KMT2AMAPTPDE4BIGF1RTTK | |
| SCHEMBL16377996 | 0.88 | CCNA2 (0.32) | MAPTROCK2PDE4BTRPV1TTK | |
| SCHEMBL22626463 | 0.87 | — | — | |
| SCHEMBL16339421 | 0.85 | CCNA2 (0.35) | MAPT | |
| SCHEMBL16377828 | 0.85 | CCNA2 (0.32) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365199-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | MERCK PATENT GMBH (DE) | 2022-06-21 | — | — | US | disclosed |
| EP-3013832-B1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2020-11-04 | — | — | EP | disclosed |
| US-20160152626-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
| US-20160152626-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11365199-B2 | Pyrazole compounds as modulators of FSHR and uses thereof | FSHR, GNRHR, LHCGR | KMT2A 2435/4885MAPT 4321/4885ROCK2 4170/4885 |
| US-20160152626-A1 | PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | KMT2A 2435/4885MAPT 4321/4885ROCK2 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.